Target Enabling Packages (TEPs)

The Target Enabling Package (TEP*) programme's foundation is built upon the recognition that genetic data is proving to be a powerful tool for target validation. As such, TEPs provide a critical mass of reagents and knowledge on a protein target to allow rapid biochemical and chemical exploration and characterisation of proteins with genetic linkage to key disease areas. TEPs provide an answer to the missing link between genomics and chemical biology, provide a starting point for chemical probe generation and therefore catalyse new biology and disease understanding with the ultimate aim of enabling translation collaborations and target/ drug discovery.

We are committed to generating and making available 24 high-quality TEPs by June 2020.


What is in a TEP?

Each TEP, as a minimum, contains:

  • Protein production methods
  • Biochemical/biophysical assays for activity, affinity etc
  • Structures of the protein, potentially including wild type and disease mutant proteins; full-length or domains; protein-ligand complexes; structures of close homologues
  • Initial chemical matter from a fragment or small molecule screen

Additional components of TEPs may be developed on a case-by-case basis, based upon reasonable scientific need, in collaboration with TEP target nominators:

  • An antibody or nanobody
  • Cell-based assay
  • CRISPR knockout



​Available TEPs

TEPs that have been approved by our external Evaluation Group are available via the links below. PDFs are available for download from these pages:

Gene Description Therapeutic Area
LIMK1 LIM domain kinase 1, human kinase domain (new) Neuropsychiatry
DCLRE1A Human DNA Cross-Link Repair 1A (new) Cancer
DPAGT1 Dolichyl-Phosphate Alpha-N-Acetyl glucosaminyl transferase (new) Neuropsychiatry and neuro genetic disorders
AASS Human alpha-aminoadipic semialdehyde synthase (new) Metabolic & Neurological disorders
WNK3 With no lysine kinase 3 (new) Metabolic diseases
HDAC6 Ubiquitin binding domain of Human HDAC6 Oncology
KDM3B Histone demethylase domain of Human KDM3B Oncology
KDM4D Histone demethylase domain of Human KDM4D Oncology
PHIP Bromodomain of Human PHIP Oncology
PfBDP4B Plasmodium falciparum Bromodomain BDP4B Infectious diseases
RECQL5 Human Helicase RECQL5 Oncology
SETDB1 Tudor domain of Human SETDB1 Oncology
CDK12 Cyclin-dependent kinase 12 (CDK12), Human kinase domain Oncology

The TEP Target List

The target list has been derived from nominations from both academia and industry with the expertise in key disease areas that are the focus of this programme: cancer, neuropsychiatry, inflammation, infectious diseases, metabolic disorders and rare diseases. Nominations are prioritised using the following criteria:

  • Robustness of available genetic disease-association data
  • Significance of disease phenotype
  • Biological plausibility
  • Need for reagents to enable post-gene work (lack of structural and biochemical data)
  • Feasibility of producing a high quality TEP with our methodologies
  • Prospects for exploiting TEPs, such as existence of downstream communities or collaborators who are committed to using the TEP

The current target list can be downloaded here.

How do I nominate targets as possible TEPs?

The target list is open for further nominations at any time using the nomination form available here which should be sent to teps[at] (subject: TEP%20Target%20Nomination) . We will get back to you as soon as possible to discuss your nominations.

How we generate and disseminate TEPs

We work closely with disease experts, clinicians, geneticists and industry experts in each of the key disease areas via our Target Prioritisation Networks (TPNs). These networks ensure that we prioritise our work on the targets which are most likely to lead to downstream utility once a TEP is released. The generation of the content of each TEP often directly involves collaborations with the nominator ensuring that that the TEP contains relevant and enabling reagents, data and knowledge.

Each TEP is carefully scrutinised by the TEP Evaluation Group, chaired by Prof. Mike Ferguson (Dundee), which makes the final decision on whether a TEP is suitable to be accepted for release to the public.

Our extensive network of partners and collaborators ensures that our TEPs are rapidly taken up and their contents used to study the biochemistry, structural and chemical biology of the target concerned.  

Need more information?

For more information regarding any aspect of TEPs and the TEP programme, please get in touch with us using the email address teps[at]

*TEP Logo designed by Claire Strain-Damerell


glqxz9283 sfy39587stf02 mnesdcuix8